Nurx parent company Thirty Madison sold to Remedy Meds in $500m all stock-deal
Thirty Madison's portfolio includes Nurx women's health brand
Nurx, one of the most prominent telehealth providers for birth control and reproductive care, is set to become part of a much larger consumer health empire. Its parent company, Thirty Madison, has agreed to be acquired by Remedy Meds in an all-stock transaction worth just over $500m, expected to close in late 2025.
Nurx has carved out a reputation as a leading player in women’s health, offering everything from contraception to STI testing through its digital platform.
Also included in the deal is Cove, known for personalized care and treatment for migraine. Both will now sit alongside Keeps (men’s hair loss) which is also from the Thirty Madison portfolio and Remedy’s own weight loss business as part of a scaled, multi-brand operation. The combined platform promises nationwide clinician access, integrated pharmacy fulfilment, and same-day telehealth visits.
Remedy Meds already reports more than $450m in annual revenue with “substantial profitability,” while Thirty Madison contributes an additional $220m+.
“By bringing together Thirty Madison's trusted brands with Remedy Med's acquisition engine, retention system, and pharmacy infrastructure, we will broaden access, shorten time-to-treatment, and maintain the financial discipline that has defined our growth," said Haris Memon, founder and CEO of Remedy Meds.
For Thirty Madison, co-founder and CEO Demetri Karagas framed the deal as a continuation of its mission to improve access to specialty care and aligns with its mission. And with the all-stock deal announced, this means Thirty Madison’s team is also betting on the future success of Remedy Medm
“Together we will deliver on making high-quality specialty care easier to access for millions of patients across the conditions we serve,” he said.
For women’s health specifically, the deal places Nurx — one of the largest telehealth providers for birth control, sexual health, and reproductive care — under the umbrella of a broader consumer health giant. That could provide potential to supercharge its growth at a time when access has never mattered more.